Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telaprevir + moxifloxacin + placebo
- Development stage
- Discontinued
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of three agents—telaprevir, moxifloxacin, and placebo. Telaprevir is an oral small molecule NS3/4A protease inhibitor used as part of combination therapy for chronic hepatitis C virus (HCV) infection, specifically genotype 1. It inhibits the HCV NS3/4A serine protease, which is essential for viral replication[1][6]. Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes necessary for bacterial DNA replication and repair. Placebo refers to an inert substance with no pharmacological effect, commonly used as a control in clinical trials.
- Brand names
- IncivekIncivoAveloxVigamox
- Other names
- TVR
02
Targets
Topo IV (Bacterial Topoisomerase IV)DNA gyraseNS3/4A (Hepatitis C virus nonstructural protein 3/4A serine protease)
Beyond the preview
Go deeper on telaprevir + moxifloxacin + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telaprevir + moxifloxacin + placebo.